Notice2023-17673
Notice; Licensing and Collaboration Opportunity
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 17, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is directed to potential peptidyl therapeutics that counteract with amyloid forming IAPP and amyloid- [beta] in treatments of diabetes and Alzheimer's disease and serve as blood-based biomarkers for Alzheimer's disease. This technology was discovered and is being developed by the National Institute on Aging (NIA). The NIA is currently seeking a licensee and/or collaborator to further develop this technology.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 158 (Thursday, August 17, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 158 (Thursday, August 17, 2023)]
[Notices]
[Pages 56026-56027]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-17673]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice; Licensing and Collaboration Opportunity
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is directed to potential peptidyl
therapeutics that counteract with amyloid forming IAPP and amyloid-
[beta] in treatments of diabetes and Alzheimer's disease and serve as
blood-based biomarkers for Alzheimer's disease. This technology was
discovered and is being developed by the National Institute on Aging
(NIA). The NIA is currently seeking a licensee and/or collaborator to
further develop this technology.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
and collaboration opportunity should be directed to: Zarpheen Jinnah,
Technology Transfer Manager, NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for
business mail), Rockville, MD 20850-9702 Telephone: (240) 276-5530;
Facsimile: (240) 276-5504 Email: <a href="/cdn-cgi/l/email-protection#255f4457554d40404b0b4f4c4b4b444d654b4c4d0b424a53"><span class="__cf_email__" data-cfemail="f08a9182809895959ede9a999e9e9198b09e9998de979f86">[email protected]</span></a>. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to this invention.
SUPPLEMENTARY INFORMATION: The following patent application is
available for licensing and/or collaboration under a Cooperative
Research and Development Agreement (CRADA):
U.S. Provisional Application No. 63/417,582.
Achieving expeditious commercialization of federally funded
research and development is consistent with the goals of the Bayh-Dole
Act, codified as 35 U.S.C. 200-212.
Background and Description of Technology: Over 34 million Americans
are living with diabetes and an estimated 6.5 million Americans are
living with Alzheimer's disease (AD). A
[[Page 56027]]
hallmark feature of type 2 diabetes mellitus (T2DM) is the accumulation
of islet amyloid polypeptide fibrils in pancreatic islets. Such
accumulations form amyloid plaques, referred to as islet amyloidosis.
Amyloidosis due to aggregation of amyloid-[beta] is key pathogenic
event in AD, whereas aggregation of mature islet amyloid polypeptide
(IAPP<INF>37</INF>) in human islet leads to [beta]-cell dysfunction.
Researchers at NIA used a bioinformatic approach to identify two novel
islet amyloid polypeptide isoforms: IAPP[beta], encoding an elongated
propeptide and non-aggregating IAPP[gamma], which is processed to
mature IAPP<INF>25</INF> instead of IAPP<INF>37</INF>. They developed a
quantitative selective reaction monitoring (SRM) proteomic assay to
measure the isoform peptide levels in human clinical plasma and CSF
from individuals with early AD and found that their levels were
significantly reduced. Further, mature IAPP<INF>25</INF> derived from
IAPP[gamma] isoform inhibits fibrillation of IAPP and amyloid-[beta]
efficiently in vitro.
Potential Commercial Applications: The novel IAPP[beta] and
IAPP[gamma] isoforms are potential peptidyl therapeutics to counteract
with amyloid forming IAPP and amyloid-[beta] in treatments of diabetes
and Alzheimer's disease and serve as blood-based biomarkers for
Alzheimer's disease.
Competitive Advantages:
<bullet> Peptide based anti-amyloid medicine.
<bullet> Potential market applications for neurodegenerative
diseases.
Development Stage: Pre-clinical (in vivo validation).
Publications: Liu, Q.-R., et al. Novel Hominid-Specific IAPP
Isoforms: Potential Biomarkers of Early Alzheimer's Disease and
Inhibitors of Amyloid Formation. (PMID 36671553) at <a href="https://pubmed.ncbi.nlm.nih.gov/36671553/">https://pubmed.ncbi.nlm.nih.gov/36671553/</a>.
Meng, Lanxia, et al. Islet amyloid polypeptide triggers [alpha]-
synuclein pathology in Parkinson's disease. (PMID 37150314)
Dated: August 11, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-17673 Filed 8-16-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 17, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.